Pathos AI Overview
- Status
-
Private
- Employees
-
85
- Latest Deal Type
-
Series E
- Latest Deal Amount
-
$237M
- Investors
-
6
Pathos AI General Information
Description
Developer of a drug discovery platform designed to reduce the duration of the medication development process. The company's self-learning platform uses big data, technology, and artificial intelligence to identify targets, validate them, and establish their clinical efficacy, enabling drug developers to explore novel concepts and advance breakthrough therapies for cancer and other diseases.
Contact Information
Website
www.pathos.comCorporate Office
- New York, NY
- United States
Corporate Office
- New York, NY
- United States
Pathos AI Timeline
Pathos AI Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series E) | 23-Oct-2026 | $237M | Completed | Clinical Trials - Phase 2 | ||
| 4. Later Stage VC (Series D) | 15-May-2025 | Completed | Clinical Trials - Phase 2 | |||
| 3. Later Stage VC (Series C) | 29-Oct-2024 | Completed | Clinical Trials - Phase 2 | |||
| 2. Early Stage VC (Series B) | 02-Mar-2023 | $30M | $40M | Completed | Clinical Trials - Phase 1 | |
| 1. Early Stage VC (Series A) | 17-Jul-2021 | $10M | $10M | Completed | Startup |
Pathos AI Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series E | ||||||||
| Series D | ||||||||
| Series C | ||||||||
| Series B | 11,076,813 | $0.000100 | 5% | $2.92 | $2.92 | 1x | $2.92 | 3.77% |
| Series A | 10,000,000 | $0.000100 | 5% | $1 | $1 | 1x | $1 | 3.41% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Pathos AI Comparisons
Industry
Financing
Details
Pathos AI Competitors (2)
One of Pathos AI’s 2 competitors is Enveda, a Venture Capital-Backed company based in Boulder, CO.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Enveda | Venture Capital-Backed | Boulder, CO | ||||
| Sygnature Discovery | Private Equity-Backed | Nottingham, United Kingdom |
Pathos AI Signals
Pathos AI Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Bristol-Myers Squibb | Corporation | Minority | ||
| New Enterprise Associates | Venture Capital | Minority | ||
| Revolution (Washington DC) | Venture Capital | Minority | ||
| Builders VC | Venture Capital | Minority | ||
| Angel (individual) | Minority |
Pathos AI Investments & Acquisitions (4)
Pathos AI’s most recent deal was a Merger/Acquisition with DeuterOncology. The deal was made on 06-May-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| DeuterOncology | 06-May-2026 | Merger/Acquisition | Drug Discovery | ||
| Envisso | 16-Mar-2026 | Seed Round | Financial Software | ||
| Rain Oncology | 26-Jan-2024 | Merger/Acquisition | Drug Delivery | ||
| Known Medicine | 23-May-2023 | Merger/Acquisition | Biotechnology |
Pathos AI Affiliates
Subsidiaries (3)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| DeuterOncology | Liege, Belgium | 2020 | |
| Known Medicine | Salt Lake City, UT | 2020 | |
| Rain Oncology | Newark, CA | 2017 |
Pathos AI FAQs
-
Where is Pathos AI headquartered?
Pathos AI is headquartered in New York, NY.
-
What is the size of Pathos AI?
Pathos AI has 85 total employees.
-
What industry is Pathos AI in?
Pathos AI’s primary industry is Discovery Tools (Healthcare).
-
Is Pathos AI a private or public company?
Pathos AI is a Private company.
-
What is the current valuation of Pathos AI?
The current valuation of Pathos AI is .
-
What is Pathos AI’s current revenue?
The current revenue for Pathos AI is .
-
How much funding has Pathos AI raised over time?
Pathos AI has raised $704M.
-
Who are Pathos AI’s investors?
Bristol-Myers Squibb, New Enterprise Associates, Revolution (Washington DC), Builders VC, and are 5 of 6 investors who have invested in Pathos AI.
-
Who are Pathos AI’s competitors?
Enveda and Sygnature Discovery are competitors of Pathos AI.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process